Pharmacodynamic Effects of Litifilimab in Lupus Supported by Recent Study

Strategic Insights -

Recent research conducted by Biogen has shed light on the pharmacodynamic effects of litifilimab on type I interferon (IFN) response and its correlations with clinical outcomes in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). The study, published in the journal Arthritis & Rheumatology, investigated the effects of litifilimab on IFN gene signature (IFNGS) scores and cytokine concentrations in participants with SLE or CLE. The findings of this study support the mechanism of action of litifilimab and its continued evaluation in larger studies of patients with SLE or CLE.

Key Takeaways:

  • Researchers at Biogen investigated the pharmacodynamic effects of litifilimab on type I interferon (IFN) response in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).
  • The study found that litifilimab induced rapid, significant reductions in type I interferon-associated gene expression and cytokine concentrations in participants with SLE or CLE.
  • The findings suggest that litifilimab may be effective in reducing inflammation associated with SLE and CLE.
  • The study included 251 participants with SLE or CLE, who received litifilimab or a placebo in a randomized, placebo-controlled phase 2 trial.
  • The research was supported by Biogen, and the findings have been peer-reviewed.
  • The study's results support the continued evaluation of litifilimab in larger studies of patients with SLE or CLE.
  • Additional authors of the study include Richard Furie, Victoria P. Werth, Eric Milliman, Kyle Ferber, Roland Brown, Jad Zoghbi, Nathalie Franchimont, and Youmna Lahoud.

Statistics:

  • The study included 251 participants with SLE or CLE.
  • 79-91% of participants were IFNGS-high at baseline.
  • Litifilimab induced rapid, significant reductions in type I interferon-associated gene expression and cytokine concentrations in 112 and 131 participants (parts A and B, respectively).
  • Nominal P-values for the reductions in IFN-associated gene expression and cytokines were reported as 0.010-0.002.

Sources:

  • NewsRx. Data on Lupus Reported by Researchers at Biogen Inc. (Pharmacodynamic Effects of Litifilimab In Lupus In a Randomized, Placebo-controlled Phase 2 Study: Rapid and Sustained Reductions In Type I Interferon-associated Gene Expression and Cytokines). Biotech Week. October 15, 2025; p 99.
  • Arthritis & Rheumatology. Pharmacodynamic Effects of Litifilimab In Lupus In a Randomized, Placebo-controlled Phase 2 Study: Rapid and Sustained Reductions In Type I Interferon-associated Gene Expression and Cytokines. 2025.